Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Net Cash Flow readings, the most recent being $24.4 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 192.09% to $24.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $32.8 million, a 104.44% increase, with the full-year FY2025 number at -$18.0 million, down 123.78% from a year prior.
  • Net Cash Flow hit $24.4 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from -$9.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $86.2 million in Q4 2024 to a low of -$59.1 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was -$1.9 million (2024), compared with a mean of $4.0 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 1116.6% in 2022 and later soared 973.05% in 2024.
  • Kiniksa Pharmaceuticals International's Net Cash Flow stood at -$53.0 million in 2022, then surged by 81.39% to -$9.9 million in 2023, then soared by 973.05% to $86.2 million in 2024, then tumbled by 110.74% to -$9.3 million in 2025, then skyrocketed by 362.97% to $24.4 million in 2026.
  • The last three reported values for Net Cash Flow were $24.4 million (Q1 2026), -$9.3 million (Q4 2025), and -$17.2 million (Q3 2025) per Business Quant data.